CASC3 and neoplasm: Taken together, BTZ+TMZ 164 mg/m2 treatment was therefore the most effective compared with other treatment protocols, where BTZ crossed the BBB and exhibited bioactivity in both tumour and non-tumour-bearing brain tissue.